Neuromuscular junction

10 min read Last updated April 9, 2026

Clinical relevance to anaesthesia

  • NMBAs act at the NMJ: understanding transmission explains onset/offset, fade, potentiation, and reversal.
    • Depolarising: persistent agonism at nicotinic ACh receptor (nAChR) → depolarisation block then desensitisation.
    • Non-depolarising: competitive antagonism at nAChR → reduced end-plate potential (EPP) and safety margin.
  • Monitoring patterns (TOF, tetanus, PTC) reflect presynaptic and postsynaptic physiology.
    • Fade is mainly due to presynaptic nAChR blockade reducing ACh mobilisation during repetitive stimulation.
  • Disease and drugs alter NMJ physiology and NMBA response.
    • Myasthenia gravis: fewer functional postsynaptic nAChRs → very sensitive to non-depolarising NMBAs, resistant to suxamethonium (often).
    • Burns/denervation/immobility: upregulation/extrajunctional spread of nAChRs → resistance to non-depolarising NMBAs, dangerous hyperkalaemia with suxamethonium.

High-yield numbers (useful in vivas)

  • Resting membrane potential (skeletal muscle): around −90 mV.
  • ACh quanta: one vesicle contains ~5,000–10,000 ACh molecules, one nerve impulse releases ~100–300 quanta (order of magnitude).
  • Synaptic cleft width: ~50 nm, NMJ has deep junctional folds increasing receptor density and safety margin.
  • nAChR channel: ligand-gated cation channel, reversal potential ~0 mV, Na+ influx predominates at resting potentials.

Anatomy and organisation of the NMJ

  • Components: motor nerve terminal, synaptic cleft with basal lamina, postsynaptic motor end-plate with junctional folds.
    • Active zones: presynaptic release sites aligned with postsynaptic junctional folds (efficient transmission).
    • Acetylcholinesterase (AChE) concentrated in basal lamina of cleft (rapid termination of ACh action).
  • Receptor distribution: high density of nAChRs at crests of junctional folds, voltage-gated Na+ channels concentrated in depths of folds (trigger AP).
  • nAChR structure: pentameric ligand-gated ion channel.
    • Adult (junctional) muscle nAChR: 2α, β, δ, ε subunits (ε replaces γ after development).
    • Fetal/extrajunctional: 2α, β, δ, γ, longer channel open time → greater K+ efflux risk when widely expressed (e.g., burns/denervation).

Presynaptic events: synthesis, storage, release of ACh

  • ACh synthesis: choline + acetyl-CoA → ACh via choline acetyltransferase (ChAT) in nerve terminal cytoplasm.
    • Choline uptake is rate-limiting (high-affinity, Na+-dependent transporter), choline largely from ACh breakdown.
  • Vesicular storage: ACh transported into vesicles by vesicular ACh transporter (VAChT).
  • Nerve action potential opens presynaptic P/Q-type voltage-gated Ca2+ channels → Ca2+ influx triggers vesicle fusion via SNARE proteins (synaptobrevin/VAMP, syntaxin, SNAP-25).
    • Botulinum toxin cleaves SNARE proteins → reduced ACh release → weakness and profound sensitivity to non-depolarising NMBAs.
    • Mg2+ and aminoglycosides reduce Ca2+-dependent ACh release → potentiate non-depolarising block.
  • Quantal release: ACh released in packets (quanta), miniature end-plate potentials (MEPPs) occur spontaneously without nerve AP.
    • MEPP amplitude reflects postsynaptic sensitivity (receptor number/function), frequency reflects presynaptic release probability.
  • Presynaptic modulation: neuronal nAChRs facilitate ACh mobilisation during repetitive stimulation, blockade contributes to fade with non-depolarising NMBAs.

Postsynaptic events: end-plate potential and muscle action potential

  • ACh binds to two α subunits on muscle nAChR → channel opens → Na+ influx (and K+ efflux) → depolarising end-plate potential (EPP).
  • EPP is a graded potential (not all-or-none) and normally exceeds threshold by a large safety margin.
    • Non-depolarising NMBAs reduce EPP amplitude by reducing the number of available receptors, when EPP fails to reach threshold → no muscle AP → paralysis.
  • Muscle AP initiation: EPP depolarises perijunctional membrane, voltage-gated Na+ channels in junctional folds open → propagated AP along sarcolemma and T-tubules.
  • Depolarising block (suxamethonium): persistent depolarisation inactivates voltage-gated Na+ channels (Phase I) → no propagated AP despite receptor activation.
    • With time/exposure: receptor desensitisation and repolarisation with persistent weakness (Phase II features) → fade may appear and anticholinesterases may partially reverse (unreliably).

Termination of transmission and recovery

  • ACh rapidly hydrolysed by acetylcholinesterase (AChE) to acetate + choline, choline recycled into nerve terminal.
  • Anticholinesterases (e.g., neostigmine): inhibit AChE → increased ACh at NMJ → outcompete non-depolarising NMBAs, also increase muscarinic effects (needs antimuscarinic).
    • Ceiling effect: if profound block (few receptors available), increasing ACh may not restore adequate EPP, reversal best when some recovery present (e.g., TOF count ≥2).
  • Sugammadex: encapsulates aminosteroid NMBAs (rocuronium &gt, vecuronium) in plasma → reduces free drug → gradient pulls drug off receptor (not dependent on AChE).

Excitation–contraction coupling (why NMJ transmission matters)

  • Muscle AP travels down T-tubules → activates dihydropyridine receptor (DHPR, L-type Ca2+ channel) mechanically coupled to ryanodine receptor (RyR1) on sarcoplasmic reticulum → Ca2+ release.
  • Ca2+ binds troponin C → moves tropomyosin → actin–myosin cross-bridge cycling (ATP-dependent) → contraction, relaxation via SERCA reuptake of Ca2+.
  • Malignant hyperthermia relates to abnormal RyR1-mediated Ca2+ release (not a primary NMJ disorder) but clinically linked to anaesthesia drugs used alongside NMBAs.

Safety margin, receptor reserve, and implications for NMBAs

  • NMJ has a large safety margin: more ACh released and more receptors available than needed to trigger a muscle AP.
    • Clinical implication: significant receptor occupancy is required before weakness appears, paralysis typically requires high receptor occupancy by non-depolarising NMBAs (often quoted ~70–95% depending on endpoint).
  • Spare receptors: maximal response can occur without all receptors being occupied, explains why partial receptor blockade may not produce clinical weakness.
  • Myasthenia gravis reduces receptor number → reduced safety margin → weakness and marked sensitivity to competitive antagonists.

Train-of-four fade, tetanus, and post-tetanic count: physiological basis

  • Non-depolarising block: TOF fade and tetanic fade due to impaired mobilisation/release of ACh during repeated stimulation (presynaptic effect) plus postsynaptic competitive antagonism.
  • Post-tetanic facilitation: tetanus increases presynaptic Ca2+ → transiently increases ACh release → temporary improvement in responses (basis of PTC during profound block).
  • Depolarising Phase I block: typically no fade (TOF ratio preserved) because presynaptic mobilisation is relatively intact, Phase II may show fade.

Factors altering NMJ transmission (drug and physiological interactions)

  • Reduce ACh release (potentiate non-depolarising block): Mg2+, aminoglycosides, polymyxins, clindamycin, calcium channel blockers (variable), local anaesthetics (high dose), lithium.
  • Alter postsynaptic sensitivity: volatile agents potentiate non-depolarising block (central and peripheral mechanisms, reduced muscle contractility and NMJ effects).
  • Acid–base/electrolytes: hypokalaemia and hypocalcaemia can increase weakness, hypermagnesaemia reduces release, acidosis may potentiate block (drug- and context-dependent).
  • Temperature: hypothermia prolongs NMBA effect (reduced metabolism/clearance and altered receptor/channel kinetics).

Developmental and pathological receptor changes (key for suxamethonium and resistance)

  • Extrajunctional (fetal-type) nAChRs appear with denervation, burns, immobilisation, upper motor neuron lesions, critical illness myopathy/neuropathy.
    • Consequences: resistance to non-depolarising NMBAs (more receptors), increased K+ efflux with suxamethonium → risk of life-threatening hyperkalaemia.
  • Myotonic dystrophy and other myopathies: unpredictable responses, avoid suxamethonium due to myotonia and potential complications (not classic hyperkalaemia mechanism like burns, but still high risk).

Test yourself…

Describe the structure of the neuromuscular junction and the distribution of receptors/ion channels.

Aim: anatomy that explains the safety margin and where NMBAs act.

  • Presynaptic terminal: motor nerve ending with synaptic vesicles containing ACh, active zones aligned with postsynaptic folds.
  • Synaptic cleft: ~50 nm, contains basal lamina rich in acetylcholinesterase (AChE).
  • Postsynaptic end-plate: junctional folds increase surface area.
    • nAChRs concentrated at crests of folds (high receptor density).
    • Voltage-gated Na+ channels concentrated deeper in folds/perijunctional membrane (AP initiation).
  • nAChR is a pentameric ligand-gated cation channel, adult receptor subunits: 2αβδε, fetal/extrajunctional: 2αβδγ.
Explain acetylcholine synthesis, storage, release, and termination at the NMJ, and relate this to drugs used in anaesthesia.

This is a common FRCA viva theme: stepwise physiology + drug interactions.

  • Synthesis: choline + acetyl-CoA → ACh via choline acetyltransferase (ChAT).
    • High-affinity choline uptake is rate-limiting, choline largely derived from ACh breakdown.
  • Storage: ACh loaded into vesicles by VAChT.
  • Release: nerve AP → presynaptic P/Q-type Ca2+ channels open → Ca2+-triggered vesicle fusion via SNARE proteins.
    • Botulinum toxin cleaves SNARE proteins → reduced ACh release → weakness, marked sensitivity to non-depolarising NMBAs.
    • Mg2+ and aminoglycosides reduce Ca2+-dependent release → potentiate non-depolarising block.
  • Termination: ACh hydrolysed by AChE in cleft → acetate + choline, choline recycled.
    • Neostigmine inhibits AChE → increases ACh → reverses competitive (non-depolarising) block, requires antimuscarinic due to muscarinic effects.
What is meant by quantal release and miniature end-plate potentials (MEPPs)? How can this be used to localise pathology to pre- or postsynaptic sites?

Often asked in physiology vivas to test understanding of synaptic transmission.

  • Quantal release: ACh released in discrete packets (quanta), each corresponding to fusion of a single vesicle.
  • MEPP: small spontaneous depolarisation at end-plate due to release of one quantum without a nerve AP.
  • Localisation concept:
    • MEPP frequency reflects presynaptic release probability (reduced in presynaptic disorders).
    • MEPP amplitude reflects postsynaptic receptor number/function (reduced in postsynaptic disorders like myasthenia).
Describe how an end-plate potential (EPP) leads to a muscle action potential and contraction. Where do NMBAs act in this sequence?

A classic integrated question: NMJ → AP → excitation–contraction coupling.

  • ACh binds nAChR → channel opens → Na+ influx/K+ efflux → EPP (graded depolarisation).
  • If EPP reaches threshold, voltage-gated Na+ channels open → propagated muscle AP along sarcolemma and T-tubules.
  • Excitation–contraction coupling: T-tubule depolarisation activates DHPR → RyR1 opens → Ca2+ release from SR → contraction via troponin/tropomyosin.
  • Sites of drug action:
    • Non-depolarising NMBAs competitively antagonise nAChR → reduce EPP amplitude.
    • Suxamethonium agonises nAChR → persistent depolarisation → Na+ channel inactivation (Phase I).
    • Volatile agents and some antibiotics/Mg2+ reduce effective transmission by pre- and postsynaptic mechanisms.
Define the ‘safety margin’ at the NMJ and explain its clinical implications for neuromuscular blockade and myasthenia gravis.

This commonly appears as a short written or viva question.

  • Safety margin: normal NMJ releases more ACh and has more functional receptors than required to reach threshold and trigger a muscle AP.
  • Clinical implications:
    • Considerable receptor occupancy by non-depolarising NMBAs is needed before weakness becomes apparent, paralysis requires high occupancy.
    • Myasthenia gravis reduces available postsynaptic nAChRs → reduced safety margin → weakness and marked sensitivity to non-depolarising NMBAs.
Explain train-of-four (TOF) fade in non-depolarising block. Why is there little/no fade in a Phase I depolarising block?

Frequently tested because it links monitoring to physiology.

  • Non-depolarising block: competitive antagonism reduces postsynaptic response, additionally, blockade of presynaptic facilitatory nAChRs reduces ACh mobilisation during repetitive stimulation → progressively smaller releases → fade.
  • Phase I depolarising block (suxamethonium): receptor is activated (not antagonised) and presynaptic mobilisation is relatively preserved, the problem is persistent depolarisation and Na+ channel inactivation → typically no TOF fade (TOF ratio ~1).
  • Phase II (with prolonged exposure): desensitisation/receptor and channel changes → fade may appear and resembles non-depolarising block.
What is post-tetanic facilitation and how does it allow post-tetanic count (PTC) monitoring during profound block?

Often asked alongside TOF and tetanus.

  • Tetanus causes sustained presynaptic depolarisation → accumulation of Ca2+ in nerve terminal → increased probability of vesicle fusion and ACh release.
  • After tetanus, transiently increased ACh release produces enhanced responses to subsequent single stimuli (post-tetanic facilitation).
  • PTC: during deep non-depolarising block with no TOF response, apply tetanus then count subsequent twitches, higher PTC predicts closer return of TOF responses.
Describe receptor subtypes at the NMJ (adult vs fetal/extrajunctional) and explain why suxamethonium can cause severe hyperkalaemia in burns/denervation.

A recurring FRCA topic: receptor biology linked to a key safety issue.

  • Adult junctional nAChR: 2αβδε, densely packed at end-plate.
  • Fetal/extrajunctional nAChR: 2αβδγ, longer channel open time and different kinetics.
  • Burns/denervation/immobility: upregulation and spread of extrajunctional receptors across muscle membrane.
  • Suxamethonium opens many more channels over a larger area → exaggerated K+ efflux → potentially life-threatening hyperkalaemia.
How do magnesium and aminoglycosides potentiate neuromuscular blockade? Include presynaptic and postsynaptic effects where relevant.

Commonly examined as ‘drug interactions with NMBAs’.

  • Magnesium: competes with Ca2+ at presynaptic voltage-gated Ca2+ channels and reduces Ca2+ entry → reduced ACh release, may also reduce postsynaptic excitability.
  • Aminoglycosides: impair Ca2+-dependent ACh release presynaptically, some also reduce postsynaptic sensitivity at higher concentrations.
  • Clinical result: increased sensitivity to non-depolarising NMBAs and prolonged block, consider dose reduction and careful monitoring.
Compare the physiological basis of Phase I and Phase II block with suxamethonium, and relate this to nerve stimulator findings and reversal.

Frequently asked because it integrates physiology, monitoring, and pharmacology.

  • Phase I: persistent depolarisation at end-plate → voltage-gated Na+ channel inactivation → no propagated AP.
    • Nerve stimulator: reduced twitch height but no fade, TOF ratio ~1, no post-tetanic facilitation.
    • Anticholinesterases: may worsen Phase I block (more ACh adds to depolarisation).
  • Phase II: with prolonged exposure/high dose → repolarisation occurs but receptors become desensitised and transmission resembles non-depolarising block.
    • Nerve stimulator: fade appears, post-tetanic facilitation may be seen.
    • Anticholinesterases: may partially reverse, but response is unpredictable, supportive management and time often required.

0 comments